Prognostic significance of multiple molecular markers for patients with stage II colorectal cancer undergoing curative resection

Annals of Surgery

Volumn 246, Issue 6, 2007, Pages 1040-1046

  Uen, Yih Huei ^a   Lin, Shiu Ru ^b   Wu, Deng Chyang ^b,c   Su, Yu Chung ^b,c   Wu, Jeng Yih ^c   Cheng, Tian Lu ^c   Chi, Chin Wen ^d   Wang, Jaw Yuan ^b,e  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; COMPLEMENTARY DNA; CYTOKERATIN 19; CYTOKERATIN 20; DIGOXIGENIN; MESSENGER RNA; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER RECURRENCE; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CANCER SURGERY; COLORECTAL CANCER; COLORIMETRY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOEMBRYONIC ANTIGEN; COLECTOMY; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KERATIN-19; KERATIN-20; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; RNA, NEOPLASM; TUMOR MARKERS, BIOLOGICAL;

EID: 36549069222     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/SLA.0b013e318142d918     Document Type: Article

References (41)

1. NIH Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990;264:1444-1450.
2. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant chemotherapy of resected colon carcinoma. N Engl J Med. 1990;322:352-358.
3. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet. 1995;345:939-944.
4. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, 5-fluorouracil and leucovorin as adjuvant treatment of colon cancer: results of the international randomized MOSAIC trial. N Engl J Med. 2004;350:2343-2351.
5. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22:23-30.
6. Moertel CG. Chemotherapy for colorectal cancer. N Engl J Med. 1994;330:1136-1142.
7. MacDonald JS. Adjuvant therapy for colon cancer. CA Cancer J Clin. 199747:243-256.
8. Figueredo A, Charette ML, Maroun J, et al. Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol. 2004;22:3395-3407.
9. Mulcahy HE, Toner M, Patchett SE, et al. Identifying stage B colorectal cancer patients at high risk of tumor recurrence and death. Dis Colon Rectum. 1997;40:326-331.
10. Andre T, Sargent D, Tabernero J, et al. Current issues in adjuvant treatment of stage II colon cancer. Ann Surg Oncol. 2006;13:887-898.
11. 0 colorectal cancer. J Gastrointest Surg. 2007;11:660-665.
12. Cascinu S, Georgoulias V, Kerr D, et al. Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factors. Ann Oncol. 2003;14:25-29.
13. Graziano F, Cascinu S. Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough? Ann Oncol. 2003;14:1026-1038.
14. Weitz J, Kienle P, Lacroix J, et al. Dissemination of tumor cells in patients undergoing surgery for colorectal cancer. Clin Cancer Res. 1998;4:343-348.
15. Wharton RQ, Jonas SK, Glover C, et al. Increased detection of circulating tumor cells in the blood of colorectal carcinoma patients using two reverse transcription-PCR assays and multiple blood samples. Clin Cancer Res. 1999;5:4158-4163.
16. Wong IH, Yeo W, Chan AT, et al. Quantitative relationship of the circulating tumor burden assessed by reverse transcription-polymerase chain reaction for cytokeratin 19 mRNA in peripheral blood of colorectal cancer patients with Dukes' stage, serum carcinoembryonic antigen level and tumor progression. Cancer Lett. 2001;167:183-191.
17. Wang JY, Wu CH, Lu CY, et al. Molecular detection of circulating tumor cells in the peripheral blood of patients with colorectal cancer using RT-PCR: significance in the prediction of postoperative metastasis. World J Surg. 2006;30:1007-1013.
18. Wang JY, Lin SR, Wu DC, et al. Multiple molecular markers as predictors of colorectal cancer in patients with normal perioperative serum CEA levels. Clin Cancer Res. 2007;13:2406-2413.
19. Chen YF, Wang JY, Wu CH, et al. Detecting circulating cancer cells with K-ras oncogene using membrane array. Cancer Lett. 2005;229:115-122.
20. Wang JY, Yeh CS, Chen YF, et al. Development and evaluation of a colorimetric membrane-array method for the detection of circulating tumor cells in the peripheral blood of Taiwanese patients with colorectal cancer. Int J Mol Med. 2006;17:737-747.
21. Yeh CS, Wang JY, Wu CH, et al. Molecular detection of circulating cancer cells in the peripheral blood of patients with colorectal cancer by using membrane array with a multiple mRNA marker panel. Int J Oncol. 2006;28:411-420.
22. International Union Against Cancer. TNM Classification of Malignant Tumors. 6th ed. New York: Wiley-Liss, Inc; 2002.
23. Wu CH, Lin SR, Yu FJ, et al. Development of a high-throughput membrane-array method for molecular diagnosis of circulating tumor cells in patients with gastric cancers. Int J Cancer. 2006;119:373-379.
24. Norum J. Adjuvant chemotherapy in Dukes' B and C colorectal carcinoma has only a minor influence on psychological distress. Support Care Cancer. 1997;5:318-321.
25. Mamounas E, Wieand S, Wolmark N, et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol. 1999;17:1349-1355.
26. Wolmark N, Colangelo L, Wieand S. National Surgical Adjuvant Breast and Bowel Project trials in colon cancer. Semin Oncol. 2001;28(1 suppl 1):9-13.
27. Jen J, Kim H, Piantadosi S, et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med. 1994;331:213-221.
28. Watanabe T, Wu TT, Catalano PJ, et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med. 2001;344:1196-1206.
29. Allegra CJ, Parr AL, Wold LE, et al. Investigation of the prognostic and predictive value of thymidylate synthase, p53 and Ki-67 in patients with locally advanced colon cancer. J Clin Oncol. 2002;20:1735-1743.
30. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349:247-257.
31. Guller U, Zajac P, Schnider A, et al. Disseminated single tumor cells as detected by real-time quantitative polymerase chain reaction represent a prognostic factor in patients undergoing surgery for colorectal cancer. Ann Surg. 2002;236:768-776.
32. Iinuma H, Okinaga K, Egami H, et al. Usefulness and clinical significance of quantitative real-time RT-PCR to detect isolated tumor cells in the peripheral blood and tumor drainage blood of patients with colorectal cancer. Int J Oncol. 2006;28:297-306.
33. Racila E, Euhus D, Weiss AJ, et al. Detection and characterization of carcinoma cells in the blood. Proc Natl Acad Sci USA. 1998;95:4589-4594.
34. Hoon DS, Wang Y, Dale PS, et al. Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol. 1995;13:2109-2116.
35. Conzelmann M, Linnemann U, Berger MR. Molecular detection of clinical colorectal cancer metastasis: how should multiple markers be put to use? Int J Colorectal Dis. 2005;20:137-146.
36. Koch M, Kienle P, Kastrati D, et al. Prognostic impact of hematogenous tumor cell dissemination in patients with stage II colorectal cancer. Int J Cancer. 2006;118:3072-3077.
37. Lloyd JM, McIver CM, Stephenson S-A, et al. Identification of early-stage colorectal cancer patients at risk of relapse post-resection by immunobead reverse transcription-PCR analysis of peritoneal lavage fluid for malignant cells. Clin Cancer Res. 2006;12:417-423.
38. Bessa X, Pinol V, Castelli-Bel S, et al. Prognostic value of postoperative detection of blood circulating tumor cells in patients with colorectal cancer operated for cure. Ann Surg. 2003;237:368-375.
39. Bosch B, Guller U, Schnider A, et al. Perioperative detection of disseminated tumor cells is an independent prognostic factor in patients with colorectal cancer. Br J Surg. 2003;90:882-888.
40. Wang Y, Jatkoe T, Zhang Y, et al. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol. 2004;22:1564-1571.
41. Northover J. Carcinoembryonic antigen and recurrent colorectal cancer. Gut. 1986;27:117-122.